A 12-year-old boy with stage 4 neuroblastoma (NB), treated according to the SIOPEN-HR-NB-01 protocol [1] , presented with recent onset of headache and vomiting at the end of the last cycle of immunotherapy with cis-retinoic acid, IL2 and CH14-18 anti-GD2 monoclonal antibody.
F-DOPA PET/computed tomography (CT) (Fig. 1e, f) showed an area of intense tracer uptake corresponding to an inhomogeneous, partly haemorrhagic, intra-axial mass lesion located in the left temporal pole, as demonstrated by the CT component of the 18 F-DOPA PET/CT study (Fig. 1g) . Increased uptake was also observed in the adjacent sphenoid bone (Fig. 1f) , with CT evidence of lytic changes along the left greater sphenoid wing (Fig. 1h, thin arrow) . This constellation of findings was consistent with skull base and CNS metastases from NB.
The patient was then treated with chemotherapy, and a post-contrast follow-up brain CT performed 4 weeks later showed reduction in size of the brain lesion (Fig. 1i , thick arrow) with ex vacuo enlargement of the left temporal horn (Fig. 1i, open arrow) .
Central nervous system (CNS) metastases in patients with NB are rare and usually result from the direct extension of skull or dural metastatic lesions [2] . At present, magnetic resonance imaging (MRI) and CT are the techniques of choice in the evaluation of CNS involvement, whereas nuclear medicine procedures, such as 123 I-meta-iodobenzylguanidine (MIBG) scan, have limited diagnostic value in detecting CNS lesions [3] .
18
F-DOPA-PET/CT has been proved to be a very sensitive technique for assessing disease extent in patients with relapsed/refractory stage 4 NB [4] [5] [6] [7] . Nevertheless, CNS lesions have never been reported. This is the first description of a brain metastasis from NB diagnosed by 18 F-DOPA PET/CT. Our case highlights the potential of 18 F-DOPA PET/CT to delineate CNS involvement, and supports the growing evidence of its value in NB diagnosis, prognosis and surveillance [8, 9] . 
